Q-omics provides the consensus-scored C9orf135-DT profile across patient tissues and cancer cell-line models. C9orf135-DT expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, C9orf135-DT is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, C9orf135-DT RNA expression shows 6,612 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight OV, KIRC, and STAD as cancer lineages where C9orf135-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C9orf135-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C9orf135-DT survival associations across molecular data types. C9orf135-DT RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C9orf135-DT RNA expression–survival associations across cancer types. High C9orf135-DT expression shows unfavorable associations in MESO, LGG, KIRC, THCA and PAAD, but favorable associations in OV. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify OV as the clearest survival context for C9orf135-DT RNA expression.
This table summarizes C9orf135-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for C9orf135-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C9orf135-DT shows lower tumor expression in KIRC, KIRP, KICH and THCA. The KIRC box plot shows higher C9orf135-DT RNA expression in normal versus tumor tissue (log2 FC = −0.012, t-test p = .019).
This table shows molecular features associated with C9orf135-DT in patient tissues and cancer cell lines. In patient samples, C9orf135-DT shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
